A composite view of cardiac rupture in the United States National Registry of Myocardial Infarction

Journal of the American College of Cardiology

Volumn 27, Issue 6, 1996, Pages 1321-1326

  Becker, Richard C ^a   Gore, Joel M ^a   Lambrew, Costas ^b   Weaver, W Douglas ^c   Rubison, R Michael ^d   French, William J ^e   Tiefenbrunn, Allen J ^f   Bowlby, Laura J ^g   Rogers, William J ^h  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b MAINE MEDICAL CENTER   (United States)

^c UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^d Southcreek Park   (United States)

^e HARBOR UCLA MEDICAL CENTER   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g GENENTECH INC   (United States)

^h UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; FIBRINOLYTIC AGENT; HEPARIN;

ARTICLE; BLOOD CLOT LYSIS; CARDIOGENIC SHOCK; CAUSE OF DEATH; CONTROLLED STUDY; HEART INFARCTION; HEART RUPTURE; HUMAN; INCIDENCE; INTRAVENOUS DRUG ADMINISTRATION; MORTALITY; ORAL DRUG ADMINISTRATION; PREVALENCE; PRIORITY JOURNAL;

EID: 0029971441     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/0735-1097(96)00008-3     Document Type: Article

References (36)

1. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarcto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment of acute myocardial infarction. Lancet 1986;1:397-402.
2. ISIS-2 (Second Internal Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349-60.
3. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: A randomised comparison of streptokinase vs. tissue plasminogen activator vs. anistreplase and of aspirin plus heparin vs. aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992;339:1-18.
4. The Fibrinolytic Therapy Trialists Collaboration. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients. Lancet 1994;343:311-22.
5. Mauri F, DeBiase AM, Franzosi MD, Pampallona S, Foresti A, Gasparini M. GISSI analisis cause di morte intraspedaliera. G Ital Cardiol 1987;17:37-44.
6. Rogers WJ, Bowlby LJ, Chandra NC, et al, for the Participants in the National Registry of Myocardial Infarction. Treatment of myocardial infarction in the United States (1990 to 1993). Observations from the National Registry of Myocardial Infarction. Circulation 1994;90:2103-14.
7. Griffith GC, Hedge B, Oblath RW. Factors in myocardial rupture. An analysis of two hundred and four cases at Los Angeles County Hospital between 1924 and 1959. Am J Cardiol 1961;12:792-8.
8. Rasmussen S, Leth A, Kjoller E, Pedersen A. Cardiac rupture in acute myocardial infarction. Acta Med Scand 1979;205:11-6.
9. Shapira I, Isakov A, Burke M, Almog CH. Cardiac rupture in patients with acute myocardial infarction. Chest 1987;92:219-23.
10. Simoons ML, Serruys PW, van den Brand M, et al. Early thrombolysis in acute myocardial infarction; limitation of infarct size and improved survival. J Am Coll Cardiol 1986;7:717-28.
11. Wilcox RG, Olsson CG, Skene AM, et al. For the ASSET Study Group. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Lancet 1988;1:525-30.
12. The TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med 1989;320:618-27.
13. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies acute myocardial infarction. N Engl J Med 1993;329:673-782.
14. Williams DO, Braunwald E, Knatterud G, et al, and the TIMI Investigators. One-year results of the thrombolysis in myocardial infarction investigation (TIMI) Phase II Trial. Circulation 1992;85:533-42.
15. Terrin ML, Williams DO, Kleiman NS, et al, for the TIMI Investigators. Two-and three-year results of the thrombolysis in myocardial infarction (TIMI) Phase II Clinical Trial. J Am Coll Cardiol 1993;22:1763-72.
16. Kleiman NS, Terrin M, Mueller H, et al, and the TIMI Investigators. Mechanisms of early death despite thrombolytic therapy: Experience from the Thrombolysis in Myocardial Infarction Phase II (TIMI II) study. J Am Coll Cardiol 1992;19:1129-35.
17. Kleiman NS, White HD, Ohman EM, et al, for the GUSTO Investigators. Mortality within 24 hours of thrombolysis from myocardial infarction: the importance of early reperfusion. Circulation 1994;90:2658-65.
18. Braunwald E, Kloner R. Prolonged postischemic ventricular dysfunction. Circulation 1982;66:1146-9.
19. Solomon SD, Ridker PM, Antman EM. Ventricular arrhythmias in trials of thrombolytic therapy for acute myocardial infarction. Circulation 1993;88: 2575-81.
20. Becker RC, Charlesworth A, Hampton J, et al, for the LATE Investigators. Cardiac rupture associated with thrombolytic therapy: impact of time to treatment in the Late Assessment of Thrombolytic Efficacy study. J Am Coll Cardiol 1995;25:1063-8.
21. Lopez-Sendon J, Gonzalez A, Lopez De Sa E, et al. Diagnosis of subacute ventricular wall rupture after acute myocardial infarction: sensitivity and specificity of clinical hemodynamic and echocardiographic criteria. J Am Coll Cardiol 1992;19:1145-53.
22. Gertz SD, Kragel AH, Kalan JM, et al. Comparison of coronary and myocardial morphologic findings in patients with and without thrombolytic therapy during fatal first myocardial infarction. Am J Cardiol 1990;66:904-9.
23. Fujwara H, Onodera T, Tanaka M, et al. Therapy and prevention. Coronary thrombolysis. A clinicopathologic study of patients with hemorrhagic myocardial infarction treated with selective coronary thrombolysis with urokinase. Circulation 1986;73:4:749-57.
24. Waller BF. The pathology of acute myocardial infarction: definition, location, pathogenesis, effects of reperfusion, complications, and sequelae. Cardiol Clin 1988;6:1-28.
25. Yasuno M, Endo S, Takahashi M, et al. Angiographic and pathologic evidence of hemorrhage into the myocardium after coronary reperfusion angiology. J Vase Dis 1984;35:797-801.
26. Gertz DS, Kalan JM, Kragel AH, et al. Cardiac morphologic findings in patients with acute myocardial infarction treated with recombinant tissue plasminogen activator. Am J Cardiol 1990;65:953-61.
27. Factor SM, Robinson TF, Dominitz R, Cho S. Alterations of the myocardial skeletal framework in acute myocardial infarction with and without ventricular rupture. A preliminary report. Am J Cardiovasc Pathol 1986;1:91-7.
28. Campbell SE, Diaz-Arias AA, Weber KT. Ventricular rupture and fibrillar collagen degradation [abstract]. Circulation 1991;84: Suppl II:II-232.
29. Charney RH, Takahashi S, Zhao M, Sonneblick EH, Eng C. Collagen loss in the stunned myocardium. Circulation 1992;85:1483-90.
30. Whittaker P, Boughner DR, Kloner RA. Role of collagen in acute myocardial infarct expansion. Circulation 1991;84:2123-34.
31. Peuhkurinen KJ, Risteli L, Melkko JT, et al. Thrombolytic therapy with streptokinase stimulates collagen breakdown. Circulation 1991;83:1969-75.
32. Dreyer WJ, Michael LH, West MS, et al. Neutrophil accumulation in ischemic canine myocardium. Circulation 1991;84:400-11.
33. Farb A, Kolodgie FD, Jenkins M, Virmani R. Myocardial infarct extension during reperfusion after coronary artery occlusion: Pathologic evidence. J Am Coll Cardiol 1993;21:1245-53.
34. Becker AE, van Mantgem J-P. Cardiac tamponade. A study of 50 hearts. Eur J Cardiology 1975;3/4:349-58.
35. Maynard C, Weaver D, Litwin P, et al, for the MITI Investigators. Hospital mortality in acute myocardial infarction in the Era of Reperfusion Therapy (the Myocardial Infarction Triage and Intervention Project (MITI). Am J Cardiol 1993;72:877-82.
36. ISIS-1 Collaborative Group. Mechanisms for the early mortality reduction produced by β-blockade started early in acute myocardial infarction. Lancet 1988;1:921-3.